Join the 'Schizophrenia' group to help and get support from people like you.

Schizophrenia Blog

Related terms: Catatonic Schizophrenia, Disorganized Schizophrenia, Paranoid Schizophrenia, Residual Schizophrenia, Schizophrenia, catatonic, Schizophrenia, disorganized, Schizophrenia, paranoid, Schizophrenia, residual, Schizophrenia, undifferentiated, Undifferentiated Schizophrenia

FDA Approves Invega Trinza (paliperidone palmitate) Four-Times-A-Year Treatment for Schizophrenia

Posted 3 days ago by Drugs.com

TITUSVILLE, N.J., May 19, 2015 – There’s a new treatment option for schizophrenia – Invega Trinza (three-month paliperidone palmitate), the first and only schizophrenia medication to be administered just four times a year, providing the longest dosing interval available. Janssen Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved under priority review the New Drug Application (NDA) for the three-month long-acting atypical antipsychotic Invega Trinza. Invega Trinza, a three-month injection, is an atypical antipsychotic indicated to treat schizophrenia. Before starting Invega Trinza, patients must be adequately treated with Invega Sustenna (one-month paliperidone palmitate) for at least four months. Priority review is a designation for drugs that, if approved, would offer significant improvement in the treatment of serious conditions. In a long- ... Read more

Related support groups: Schizophrenia, Invega, Invega Sustenna, Paliperidone

First Generic Abilify Approved

Posted 29 Apr 2015 by Drugs.com

WEDNESDAY, April 29, 2015 – The first generic versions of the atypical antipsychotic drug Abilify (aripiprazole) have been approved by the U.S. Food and Drug Administration to treat schizophrenia or bipolar disorder. License to produce the drug in multiple strengths was approved for Alembic Pharmaceuticals, Hetero Labs, Teva Pharmaceuticals, and Torrent Pharmaceuticals, the agency said in a news release. Bipolar disorder, also known as manic depression or manic-depressive illness, is a brain disorder that causes unusual moods and activities, affecting the ability to carry out day-to-day tasks. Symptoms typically include alternating periods of depression (lows) and increased activity and restlessness (highs). Schizophrenia, another brain disorder, affects about 1 percent of Americans. Symptoms typically begin in people younger than 30, and include hearing voices, believing other people ... Read more

Related support groups: Bipolar Disorder, Seroquel, Abilify, Mania, Schizophrenia, Zyprexa, Risperdal, Risperidone, Geodon, Schizoaffective Disorder, Saphris, Latuda, Seroquel XR, Quetiapine, Olanzapine, Invega, Clozapine, Aripiprazole, Clozaril, Ziprasidone

FDA Approves First Generic Abilify (aripiprazole) to Treat Mental Illnesses

Posted 28 Apr 2015 by Drugs.com

April 28, 2015 – The U.S. Food and Drug Administration today approved the first generic versions of Abilify (aripiprazole). Generic aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder. Alembic Pharmaceuticals Ltd., Hetero Labs Ltd., Teva Pharmaceuticals and Torrent Pharmaceuticals Ltd. have received FDA approval to market generic aripiprazole in multiple strengths and dosage forms. “Having access to treatments is important for patients with long-term health conditions,” said John Peters, M.D., acting director of the Office of Generic Drugs in the FDA’s Center for Drug Evaluation and Research. “Health care professionals and consumers can be assured that FDA-approved generic drugs have met the same rigorous standards as the brand-name drug.” Schizophrenia is a chronic, severe and disabling brain disorder. About one percent of Americans ha ... Read more

Related support groups: Bipolar Disorder, Abilify, Schizophrenia, Aripiprazole, Abilify Discmelt, Abilify Maintena

FDA Medwatch Alert: Zyprexa Relprevv (olanzapine pamoate): Drug Safety Communication - FDA Review of Study Sheds Light on Two Deaths Associated with the Injectable Schizophrenia Drug

Posted 23 Mar 2015 by Drugs.com

ISSUE: FDA has concluded a review of a study undertaken to determine the cause of elevated levels of the injectable schizophrenia drug Zyprexa Relprevv (olanzapine pamoate) in two patients who died. The study results were inconclusive. FDA is unable to exclude the possibility that the deaths were caused by rapid, but delayed, entry of the drug into the bloodstream following intramuscular injection. The study suggested that much of the drug level increase could have occurred after death, a finding that could explain the extremely high blood levels found in the two patients who died 3 to 4 days after receiving injections of appropriate doses of Zyprexa Relprevv. On the basis of all of the information reviewed (refer to the Drug Safety Communication for a full data summary), FDA is not recommending any changes to the current prescribing or use of Zyprexa Relprevv injection at this time. ... Read more

Related support groups: Schizophrenia, Zyprexa, Olanzapine, Zyprexa Relprevv

Study Highlights Complexity of 'Hearing Voices'

Posted 11 Mar 2015 by Drugs.com

WEDNESDAY, March 11, 2015 – Rachel Waddingham hears voices. "I hear about 13 or so voices," she said in a news release from Durham University, in England. "Each of them is different – some have names, they are different ages and sound like different people. Some of them are very angry and violent, others are scared, and others are mischievous." In fact, "for me, the word 'voices' isn't sufficient," said Waddingham, a trustee of the National Hearing Voices Network in the United Kingdom, and the International Society for Psychological and Social Approaches to Psychosis. She said that while she uses the word voices to convey her experience, the word also "hides the embodied parts of my experience for which I have few words to describe." Now, a new study from Durham University highlights the complexity and variety of the "voices" some psychiatric patients and others experience. The study ... Read more

Related support groups: Schizophrenia, Schizoaffective Disorder

Mental Health Disorders May Shorten Life Span: Study

Posted 11 Feb 2015 by Drugs.com

WEDNESDAY, Feb. 11, 2015 – People with mental health conditions such as depression, chronic anxiety and schizophrenia tend to die at younger ages than their peers without psychiatric disorders, a new research review says. In fact, the researchers estimated that mental health disorders typically rob people of nearly a decade of life, and account for 8 million deaths worldwide each year. The findings, published online Feb. 11 in JAMA Psychiatry, come from an analysis of over 200 international studies spanning several decades. Researchers said the studies help put the global toll of mental health disorders into perspective. Although the study found an association between mental health conditions and earlier death, it wasn't designed to prove that the disorders were a direct cause of the early deaths. When people think of lives lost to mental illness, they might automatically focus on one ... Read more

Related support groups: Anxiety, Depression, Schizophrenia, Psychiatric Disorders

FDA Medwatch Alert: Ziprasidone (Marketed as Geodon and Generics): Drug Safety Communication - Rare But Potentially Fatal Skin Reactions

Posted 11 Dec 2014 by Drugs.com

ISSUE:  FDA is warning that the antipsychotic drug ziprasidone (marketed under the brand name, Geodon, and its generics) is associated with a rare but serious skin reaction that can progress to affect other parts of the body. A new warning has been added to the Geodon drug label to describe the serious condition known as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). See the FDA Drug Safety Communication for a Data Summary and additional information. DRESS may start as a rash that can spread to all parts of the body. It can include fever, swollen lymph nodes, and inflammation of organs such as the liver, kidney, lungs, heart, or pancreas. DRESS also causes a higher-than-normal number of a particular type of white blood cell called eosinophils in the blood. DRESS can lead to death. BACKGROUND: Ziprasidone is an atypical antipsychotic drug used to treat schizophrenia and ... Read more

Related support groups: Bipolar Disorder, Schizophrenia, Geodon, Ziprasidone

FDA Approves Labeling Update Of Abilify Maintena for Acutely Relapsed Adults With Schizophrenia

Posted 10 Dec 2014 by Drugs.com

Tokyo, Japan and Valby, Denmark – December 6, 2014 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced that the U.S. Food and Drug Administration (FDA) approved the labeling update of Abilify Maintena (aripiprazole) for extended-release injectable suspension. The approval was based on results from a controlled clinical study of acutely relapsed adults with schizophrenia. Efficacy was demonstrated in a 12-week randomized, double-blind, placebo-controlled study, which showed treatment with Abilify Maintena (with concomitant oral aripiprazole for the first two weeks) significantly improved symptoms with an acceptable safety and tolerability profile in adult patients experiencing an acute relapse of schizophrenia.1 These data were published in the November print edition of The Journal of Clinical Psychiatry. 2 Abilify Maintena, an atypical antipsychotic, was ... Read more

Related support groups: Abilify, Schizophrenia, Aripiprazole, Abilify Maintena

Study Finds Need for Improved Schizophrenia Care

Posted 8 Dec 2014 by Drugs.com

THURSDAY, Dec. 4, 2014 – Improper drug treatment is given to nearly 40 percent of people who suffer their first episode of schizophrenia, according to a new study. Because schizophrenia is typically a chronic illness, early treatment can have an effect on a patient's long-term outcome, the researchers noted. Inappropriate drug treatment can lead to problems that cause patients to stop taking their medication. The study included 404 people who suffered a first episode of schizophrenia. They were seen at community treatment centers in 21 states. Of those patients, 159 received drug treatment that was inconsistent with recommendations for first-episode patients. Some of the more common mistakes the researchers cited included: Prescribing more than one antipsychotic drug. A higher-than-recommended dose of an antipsychotic. The use of psychotropic medication other than an antipsychotic. ... Read more

Related support groups: Schizophrenia

FDA Approves Dual-Chamber Syringe for Abilify Maintena (aripiprazole) for Schizophrenia

Posted 1 Oct 2014 by Drugs.com

Princeton, N.J. and Deerfield, Ill. – September 29, 2014 – Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration (FDA) has approved a new formulation of Abilify Maintena (aripiprazole) for extended-release injectable suspension – a pre-filled dual-chamber syringe. Abilify Maintena is an atypical antipsychotic indicated for the treatment of schizophrenia; efficacy was demonstrated in a placebo-controlled, randomized-withdrawal maintenance trial in patients with schizophrenia and additional support for efficacy was derived from oral aripiprazole trials. The companies expect the dual-chamber syringe will be available in the U.S. in January 2015. “Since March 2013, Abilify Maintena has been an important treatment option for people living with schizophrenia. Otsuka and Lundbeck continue to be committed to ... Read more

Related support groups: Abilify, Schizophrenia, Aripiprazole, Abilify Maintena

Stem Cell Research Offers Clues About Schizophrenia

Posted 12 Sep 2014 by Drugs.com

FRIDAY, Sept. 12, 2014 – New research involving stem cells may provide clues about the chemical basis for schizophrenia, scientists report. Brain cells of people with this chronic and disabling brain disorder give off higher amounts of three neurotransmitters linked to a range of psychiatric disorders, researchers found. Neurotransmitters are chemicals that trigger or block the transmission of electrical signals in the brain. Although the cause of schizophrenia remains unknown and there is no cure, the study authors suggested their findings shed new light on the chemical basis of the disorder. Ultimately, they believe the study results could help scientists treat patients with schizophrenia more effectively. "The study provides new insights into neurotransmitter mechanisms in schizophrenia that can lead to new drug targets and [treatments]," study senior author Vivian Hook, a professor ... Read more

Related support groups: Schizophrenia

People With OCD May Have Higher Odds for Schizophrenia: Study

Posted 3 Sep 2014 by Drugs.com

WEDNESDAY, Sept. 3, 2014 – People with obsessive-compulsive disorder (OCD) may be at higher risk for schizophrenia, a new study suggests. Still, the findings shouldn't cause undue worry in people with OCD, one expert said. "In the general population, about 1 percent of people are diagnosed with schizophrenia – a proportion that jumps to 2 percent among those who already have a diagnosis of OCD," explained Dr. Alan Manevitz, who was not involved in the study but reviewed its findings. "But even with this doubled risk, it would be alarmist to suggest that a person with OCD has a high chance of developing schizophrenia," said Manevitz, a clinical psychiatrist at Lenox Hill Hospital in New York City. "In fact, that risk remains small." While OCD and schizophrenia are two distinct mental disorders, prior research has suggested a link between the two conditions. In the new study, Danish ... Read more

Related support groups: Obsessive Compulsive Disorder, Schizophrenia

Many With Schizophrenia Say They're Happy: Study

Posted 20 Aug 2014 by Drugs.com

TUESDAY, Aug. 19, 2014 – Even though schizophrenia is one of the most severe forms of mental illness, nearly 40 percent of people with the disorder say they're happy, new research contends. Researchers at the University of California, San Diego, surveyed 72 schizophrenia patients, ranging in age from 23 to 70, living in the San Diego area, and found that 37 percent said they were happy all or most of the time. Their happiness wasn't related to the length or severity of their mental illness, to their mental or physical status, or to factors such as age and education. Instead, their happiness was associated with positive mental and social characteristics such as optimism, resilience and lower stress levels, the researchers said. The findings are valuable because these positive traits can be taught to many people, said the authors of the study, which was published online Aug. 18 in the ... Read more

Related support groups: Schizophrenia

Certain Antipsychotic Meds Tied to Kidney Problems in Elderly

Posted 19 Aug 2014 by Drugs.com

TUESDAY, Aug. 19, 2014 – Kidney injury can be added to the list of possible harms related to use of three antipsychotic medications often prescribed to treat behavioral symptoms of dementia in older adults, a new study finds. Quetiapine (Seroquel), risperidone (Risperdal) and olanzapine (Zyprexa) are approved by the U.S. Food and Drug Administration to treat bipolar disorder, schizophrenia and other serious mental disorders. They are also frequently used "off-label" to treat behavioral concerns such as aggression or agitation in seniors with Alzheimer's and similar neurodegenerative diseases. "The side effect profile with antipsychotics is particularly concerning, so there is ample evidence to worry about their use in older adults unless they're absolutely necessary," said Dr. Anton Porsteinsson, director of Alzheimer's disease care, research and education at the University of ... Read more

Related support groups: Seroquel, Schizophrenia, Zyprexa, Risperdal, Risperidone, Seroquel XR, Quetiapine, Olanzapine, Zyprexa Zydis, Risperdal Consta, Risperdal M-Tab, Zyprexa Intramuscular, Zyprexa Relprevv

Gene Discoveries Could Shed New Light on Schizophrenia

Posted 22 Jul 2014 by Drugs.com

TUESDAY, July 22, 2014 – One of the largest studies ever conducted into the genetic origins of a psychiatric disorder has uncovered 83 new sites on chromosomes that harbor inherited genes tied to schizophrenia. The findings, made by an international team of researchers, now bring the total number of common gene variants linked to the disorder to 108. Although these schizophrenia-associated genes aren't specific enough to be used as a test to predict who will or will not develop the illness, researchers say they might someday be used as a screening tool for high-risk people who may benefit from preventative treatments. Right now, the total group of schizophrenia-linked genes "only explains only about 3.5 percent of the risk for schizophrenia," Dr. Thomas Insel, director of the U.S. National Institute of Mental Health, said in an agency news release. However, "even based on these early ... Read more

Related support groups: Schizophrenia

Page 1 2 3 4 5 6 Next

Ask a Question

Further Information

Related Condition Support Groups

Schizoaffective Disorder, Psychiatric Disorders

Related Drug Support Groups

Seroquel, Abilify, Zyprexa, Risperdal, risperidone, Geodon, Saphris, Latuda, Seroquel XR, view more... quetiapine, olanzapine, Invega, clozapine, Thorazine, aripiprazole, Clozaril, Fanapt, ziprasidone, chlorpromazine, Invega Sustenna, Zyprexa Zydis, paliperidone, asenapine, Risperdal Consta, Stelazine, thioridazine, Mellaril, loxapine, trifluoperazine, iloperidone, Loxitane, Risperdal M-Tab, lurasidone, Zyprexa Intramuscular, Moban, reserpine, Abilify Maintena, Clopine, Abilify Discmelt, mesoridazine, molindone, Versacloz, Adasuve, Zyprexa Relprevv, Zaponex, Clozapine Synthon, Ormazine, FazaClo, Denzapine, Mellaril-S, Loxitane C, Serentil, Loxitane IM